Login to Your Account



Valeant wins FDA approval for Siliq

By Michael Fitzhugh
Staff Writer

Friday, February 17, 2017

Valeant Pharmaceuticals International Inc. won a widely anticipated FDA approval for its moderate to severe plaque psoriasis drug, Siliq (brodalumab), complete with an expected black box warning for suicidal ideation and behavior that analysts expect could hamper sales. U.S. availability of the drug, licensed from Astrazeneca plc, is set for the second half of this year. Acceptance of the drug's EMA marketing authorization application arrived in late 2015.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription